Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (5): 845-852. doi: 10.19723/j.issn.1671-167X.2024.05.015

Previous Articles     Next Articles

Diagnostic values of anti-salivary gland protein-1 antibody combined with anti-parotid secretory protein antibody for Sjögren's syndrome

Yushu YANG, Xuan QI, Meng DING, Wei WANG, Huifang GUO, Lixia GAO*()   

  1. Department of Rheumatology and Immunology, the Second Hospital of Hebei Medical University, Shijiazhuang 050011, China
  • Received:2023-10-16 Online:2024-10-18 Published:2024-10-16
  • Contact: Lixia GAO E-mail:27100287@hebmu.edu.cn
  • Supported by:
    Hebei Province Science and Technology Department, Science and Technology Project for People's Livelihood of Key Research and Development Programs(20377782D)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To assess the diagnostic value of anti-salivary gland protein-1 (SP1) antibody combined with anti-parotid secretory protein (PSP) antibody for Sjögren's syndrome (SS). Methods: A total of 60 patients with primary SS (pSS) who were treated in the outpatient and inpatient department of Department of Rheumatology and Immunology of the Second Hospital of Hebei Medical University from January 2020 to December 2022 were collected. Thirty patients with other autoimmune diseases accompanied by dry mouth and/or dry eyes were collected as disease control group. Thirty healthy subjects from the physical examination center were collected for healthy control group, serum samples were obtained from all of them. Their general features and clinical information including clinical manifestations, laboratory examinations and other examinations were recorded. The 2016 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) classification criteria were adopted as the diagnostic standard of pSS. Immunoglobulin G (IgG) subtype of anti-SP1 antibody and anti-PSP antibody were detected by chemiluminescence immunoassay. The receiver operating characteristic (ROC) curve was used to evaluate the accuracy of anti-SP1 antibody and anti-PSP antibody in diagnosing pSS.The cli-nical characteristics of anti-SP1 antibody and anti-PSP antibody positive patients and negative patients in pSS group were further compared. Independent samples t test, Mann-Whitney U test, variance analysis, Kruskal-Wallis test, Chi-square test or Fisher's exact test and Spearman correlation analysis were used for statistical analysis. Results: There was no significant difference in age (F=1.406, P=0.495) and gender (χ2=2.105, P=0.349) among pSS group, disease control group and healthy control group. The expression levels of anti-SP1 antibody (H=16.73, P < 0.001) and anti-PSP antibody (H=26.09, P < 0.001) were statistically different among the three groups. An intergroup comparison of anti-SP1 antibody expression levels showed that there was a statistically significant difference between pSS and healthy control group (P < 0.001), but no statistically significant difference between the other groups. Comparison of anti-PSP antibody expression levels between the groups showed that there were statistically significant differences between pSS and healthy control group (P < 0.001), and between disease control group and healthy control group (P=0.009), while no statistically significant differences between the other groups. The positive rate of anti-SP1 antibody in pSS group was significantly higher than that in disease control group and healthy control group (58.33% vs. 40.00% vs. 13.33%, P < 0.001). The positive rate of anti-PSP antibody in pSS group was significantly higher than that in disease control group and healthy control group (75.00% vs. 56.17% vs. 16.67%, P < 0.001). The area under the curve for anti-SP1 antibody was 0.688 (P < 0.001). The sensitivity and specificity of anti-SP1 antibody were 58.33% (35/60) and 70.00% (42/60) respectively, the positive predictive value was 66.04% (35/53) and the negative predictive value was 54.55% (42/77) of anti-SP1 antibody.The area under the curve of anti-PSP antibody was 0.720 (P < 0.001), with a sensitivity was 75.00% (45/60), and specificity was 63.33% (38/60).The positive predictive value and negative predictive value of anti-PSP antibody were 67.16% (45/67) and 71.70% (38/53) respectively. All the 13 pSS patients were negative for anti-Sjögren's syndrome A (SSA, including SSA52 and SSA60) antibody and anti- Sjögren's syndrome B (SSB) antibody. Among them, 11 patients were positive for both anti-SP1 antibody and anti-PSP antibody, 1 patient was positive for anti-SP1 antibody and 1 patient was positive for anti-PSP antibody. The clinical features of anti-SP1 antibody and anti-PSP antibody positive and negative groups were compared in pSS patients. The duration of disease in anti-SP1 antibody positive group was shorter (Z=-2.277, P=0.023) when compared with the negative patients. The patients with positive anti-PSP antibody were younger than those in the negative group (t=2.598, P < 0.05), the positive rate of rheumatoid factor (P=0.002) and the serum level of IgG (t=3.806, P=0.003) in anti-PSP antibody positive group were higher than in the negative group. Analysis of the correlation between anti-SP1 antibody and anti-PSP antibody in the pSS patients showed that there was significant correlation between them (r=0.801, P < 0.001). Conclusion: Both anti-SP1 antibody and anti-PSP antibody are valuable in the diagnosis of SS, and anti-SP1 antibody is helpful for the early diagnosis of pSS. The combined detection of anti-SP1 antibody and anti-PSP antibody is helpful for the early diagnosis of pSS patients with negative anti-SSA antibody and anti-SSB antibody.

Key words: Sjögren's syndrome, Anti-salivary gland protein 1 antibody, Anti-parotid secretory protein antibody

CLC Number: 

  • R593.2

Table 1

Comparison of anti-SP1 antibody and anti-PSP antibody expression levels among three groups"

Items pSS Disease control Healthy control H P
Anti-SP1 antibody/ (U/mL)，M (P25, P75) 8.93 (5.43, 17.04) 6.21 (4.01, 11.97) 5.08 (3.05, 6.85) 16.73 0.002
Anti-PSP antibody/(U/mL), M (P25, P75) 7.02 (4.58, 13.34) 4.86 (3.45, 8.88) 2.67 (2.29, 4.24) 26.09 < 0.001

Figure 1

Level of serum anti-SP1 antibody in study subjects (cutoff value 7.9 U/mL) pSS, primary Sjögren's syndrome; SP1, salivary protein 1."

Figure 2

Level of serum anti-PSP antibody in study subjects (cutoff value 4.6 U/mL) pSS, primary Sjögren's syndrome; PSP, parotid secretory protein."

Figure 3

Receiver operating characteristic curve of anti-SP1 antibody and anti-PSP antibody in diagnosis of Sjögren's syndrome SP1, salivary protein 1; PSP, parotid secretory protein; AUC, area under the curve."

Table 2

Comparison of the clinical features of anti-SP1 antibody positive and negative pSS patients"

Items Anti-SP1antibody(+) (n=35) Anti-SP1antibody(-) (n=25) t/Z/χ2 P
Age/years,$\bar{x} \pm s$ 49.3±13.3 52.5±13.3 0.903 0.371
Female, n (%) 34 (97.1) 24 (96.0) ＞0.999a
Duration/months, M (P25, P75) 21 (10, 36) 36 (15, 60) -2.277 0.023
WBC/(×109/L),$\bar{x} \pm s$ 5.2±1.6 4.3±1.7 1.489 0.142
PLT/(×109/L),$\bar{x} \pm s$ 181.1±71.2 180.5±91.0 0.027 0.979
IgG/(g/L),$\bar{x} \pm s$ 19.1±8.9 20.7±7.2 1.519 0.303
RF/(U/mL), n (%) 13 (52.0) 15 (42.9) 0.490 0.488
ANA, n (%) 23 (92.0) 33 (94.3) ＞0.999a
Anti-SSA52, n (%) 20 (80.0) 23 (65.7) 1.466 0.226
Anti-SSA60, n (%) 16 (64.0) 19 (54.3) 0.566 0.452
Anti-SSB, n (%) 7 (28.0) 7 (25.0) 0.522 0.470
ACA, n (%) 3 (12.0) 3 (8.6) 0.686a
Biopsy, n (%) 19 (76.0) 27 (77.1) 2.307 0.511
Oral dryness, n (%) 30 (85.7) 23 (92.0) 0.688a
Ocular dryness, n (%) 20 (57.1) 15 (60.0) ＞0.999a
ILD, n (%) 13 (37.1) 10 (40.0) ＞0.999a
Enlargemen of salivary glands, n (%) 7 (20.0) 1 (4.0) 0.123a
Rash, n (%) 7 (28.0) 7 (25.0) 0.522 0.470
ITP, n (%) 6 (17.1) 4 (16.0) ＞0.999a

Table 3

Comparison of the clinical features of anti-PSP antibody positive and negative pSS patients"

Items Anti-PSP antibody(+) (n=45) Anti-PSP antibody(-) (n=15) t/Z/ χ2 P
Age/years,$\bar{x} \pm s$ 48.2±13.7 58.0±8.8 2.598 0.012
Female, n (%) 43 (95.6) 15 (100) ＞0.999a
Duration/months, M (P25, P75) 24 (12, 48) 30 (12, 57) -1.414 0.157
WBC/(×109/L),$\bar{x} \pm s$ 4.9±2.4 4.8±1.9 0.097 0.923
PLT/(×109/L),$\bar{x} \pm s$ 179.2±87.7 185.6±67.7 0.252 0.802
IgG/(g/L),$\bar{x} \pm s$ 21.8±7.9 13.5±2.6 3.086 0.003
RF/(U/mL), n (%) 27 (60.0) 2 (1.3) 0.002a
ANA, n (%) 42 (93.3) 14 (93.3) ＞0.999a
Anti-SSA52, n (%) 33 (73.3) 10 (66.7) 0.246 0.620
Anti-SSA60, n (%) 27 (60.0) 8 (53.3) 0.208 0.650
Anti-SSB, n (%) 15 (33.3) 3 (20.0) 0.517a
ACA, n (%) 3 (6.7) 3 (20.0) 0.159a
Biopsy, n (%) 33 (73.3) 13 (86.7) 2.115 0.159
Oral dryness, n (%) 39 (86.7) 14 (6.9) 0.668a
Ocular dryness, n (%) 26 (57.8) 9 (60.0) ＞0.999a
ILD, n (%) 17 (37.8) 6 (40.0) ＞0.999a
Enlargemen of salivary glands, n (%) 7 (15.6) 1 (6.7) 0.656a
Rash, n (%) 10 (22.2) 4 (26.7) 0.734a
ITP, n (%) 8 (17.8) 2 (13.3) ＞0.999a

Figure 4

Correlation between anti-SP1 antibody and anti-PSP antibody in patients with Sjögren's syndrome SP1, salivary protein 1; PSP, parotid secretory protein."

1 Goules AV , Argyropoulou OD , Pezoulas VC , et al. Primary Sjögren's syndrome of early and late onset: Distinct clinical phenotypes and lymphoma development[J]. Front Immunol, 2020, 11, 594096.
2 Vitali C , Bombardieri S , Jonsson R , et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61 (6): 554- 558.
3 Shiboski SC , Shiboski CH , Criswell L , et al. American College of Rheumatology classification criteria for Sjögren's syndrome: A data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort[J]. Arthritis Care Res (Hoboken), 2012, 64 (4): 475- 487.
4 Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Ann Rheum Dis, 2017, 76 (1): 9- 16.
5 Hoshina Y , Wong KH , Galli J , et al. Neurologic involvement in seronegative primary Sjögren's syndrome with positive minor salivary gland biopsy: A single-center experience[J]. Front Neurol, 2023, 14, 1174116.
6 Chen J , He Q , Yang J , et al. Anti-SSA/SSB-negative primary Sjögren's syndrome showing different clinical phenotypes: A retrospective study of 934 cases[J]. Adv Rheumatol, 2023, 63 (1): 21.
7 Bodeutsch C , de Wilde PC , Kater L , et al. Labial salivary gland biopsy in Sjögren's syndrome[J]. Neth J Med, 1992, 40 (3/4): 148- 157.
8 Theander E , Jonsson R , Sjöström B , et al. Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling[J]. Arthritis Rheumatol, 2015, 67 (9): 2427- 2436.
9 Jonsson R , Theander E , Sjöström B , et al. Autoantibodies present before symptom onset in primary Sjögren syndrome[J]. JAMA, 2013, 310 (17): 1854- 1855.
10 Lee AYS , Lin MW . Serological intermolecular epitope spreading in a patient with primary Sjögren's syndrome[J]. BMJ Case Rep, 2023, 16 (5): e254632.
11 Mona M , Mondello S , Hyon JY , et al. Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjögren's syndrome[J]. Clin Exp Rheumatol, 2021, 39 (4): 795- 803.
12 Alam J , Koh JH , Kwok SK , et al. Functional epitopes for anti-aquaporin 5 antibodies in Sjögren syndrome[J]. J Dent Res, 2017, 96 (12): 1414- 1421.
13 Alam J , Koh JH , Kim N , et al. Detection of autoantibodies against aquaporin-5 in the sera of patients with primary Sjögren's syndrome[J]. Immunol Res, 2016, 64 (4): 848- 856.
14 Tjensvoll AB , Lauvsnes MB , Zetterberg H , et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome[J]. Journal of Neurology, 2021, 268 (4): 1385- 1394.
15 Shen L , Gao C , Suresh L , et al. Central role for marginal zone B cells in an animal model of Sjögren's syndrome[J]. Clin Immunol, 2016, 168, 30- 36.
16 Jin Y , Li J , Chen J , et al. Tissue-specific autoantibodies improve diagnosis of primary Sjögren's syndrome in the early stage and indicate localized salivary injury[J]. J Immunol Res, 2019, 2019, 3642937.
17 Shen L , Suresh L , Lindemann M , et al. Novel autoantibodies in Sjögren's syndrome[J]. Clin Immunol, 2012, 145 (3): 251- 255.
18 Xuan J , Wang Y , Xiong Y , et al. Investigation of autoantibodies to SP-1 in chinese patients with primary Sjögren's syndrome[J]. Clin Immunol, 2018, 188, 58- 63.
19 Xian Z , Fu D , Liu S , et al. Association between B cell growth factors and primary Sjögren's syndrome-related autoantibodies in patients with non-Hodgkin's lymphoma[J]. J Immunol Res, 2019, 2019, 7627384.
20 Bunya VY , Massaro-Giordano M , Vivino FB , et al. Prevalence of novel candidate Sjögren syndrome autoantibodies in the penn Sjögren's International Collaborative Clinical Alliance Cohort[J]. Cornea, 2019, 38 (12): 1500- 1505.
21 Shen L , Kapsogeorgou EK , Yu M , et al. Evaluation of salivary gland protein 1 antibodies in patients with primary and secondary Sjögren's syndrome[J]. Clin Immunol, 2014, 155 (1): 42- 46.
22 Applbaum E , Lichtbroun A . Novel Sjögren's autoantibodies found in fibromyalgia patients with sicca and/or xerostomia[J]. Autoimmun Rev, 2019, 18 (2): 199- 202.
23 de Langhe E , Bossuyt X , Shen L , et al. Evaluation of autoantibodies in patients with primary and secondary Sjögren's syndrome[J]. Open Rheumatol J, 2017, 11, 10- 15.
24 Hubschman S , Rojas M , Kalavar M , et al. Association between early Sjögren markers and symptoms and signs of dry eye[J]. Cornea, 2020, 39 (3): 311- 315.
25 Geetha C , Venkatesh SG , Dunn BH , et al. Expression and anti-bacterial activity of human parotid secretory protein (PSP)[J]. Biochem Soc Trans, 2003, 31 (Pt 4): 815- 818.
26 Karakus S , Baer AN , Akpek EK . Clinical correlations of novel autoantibodies in patients with dry eye[J]. J Immunol Res, 2019, 2019, 7935451.
27 Burbelo PD , Ferré E , Chaturvedi A , et al. Profiling autoanti-bodies against salivary proteins in sicca conditions[J]. J Dent Res, 2019, 98 (7): 772- 778.
28 Thatayatikom A , Jun I , Bhattacharyya I , et al. The diagnostic performance of early Sjögren's syndrome autoantibodies in juvenile Sjögren's syndrome: The university of florida pediatric cohort study[J]. Front Immunol, 2021, 12, 704193.
29 Lee KA , Kim KW , Kim BM , et al. Clinical and diagnostic signi-ficance of serum immunoglobulin A rheumatoid factor in primary Sjögren's syndrome[J]. Clin Oral Investig, 2019, 23 (3): 1415- 1423.
30 Zhong H , Wang Y , Yang P , et al. Hyperglobulinemia predicts increased risk of mortality in primary Sjögren's syndrome: Based on a Chinese multicentre registry[J]. Mod Rheumatol, 2023, 34 (1): 137- 143.
31 Kota SK , Pernicone E , Leaf DE , et al. BPI fold-containing family a member 2/parotid secretory protein is an early biomarker of AKI[J]. J Am Soc Nephrol, 2017, 28 (12): 3473- 3478.
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183.
[3] Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017.
[4] Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023.
[5] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[6] Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[7] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8] Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060.
[9] Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066.
[10] Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073.
[11] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[12] Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095.
[13] Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[14] Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112.
[15] Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd